Models for evaluating agents intended for the prophylaxis, mitigation and treatment of radiation injuries report of an NCI workshop, December 3-4, 2003

Radiation Research

Volumn 162, Issue 6, 2004, Pages 711-728

  Stone, Helen B ^a,o   Moulder, John E ^b   Coleman, C Norman ^a   Ang, K Kian ^c   Anscher, Mitchell S ^d   Barcellos Hoff, Mary Helen ^e   Dynan, William S ^f   Fike, John R ^g   Grdina, David J ^h   Greenberger, Joel S ⁱ   Hauer Jensen, Martin ^j   Hill, Richard P ^k   Kolesnick, Richard N ^l   MacVittie, Thomas J ^m,o   Marks, Cheryl ^a   McBride, William H ^n,p   Metting, Noelle ^m,o   Pellmar, Terry ^n,p   Purucker, Mary ^q   Robbins, Mike E ^r   Schiestl, Robert H ^n,p   Seed, Thomas M ^s   Tomaszewski, Joseph E ^a   Travis, Elizabeth L ^c   Wallner, Paul E ^a   Wolpert, Mary ^a   Zaharevitz, Daniel ^a   more..

^a NATIONAL CANCER INSTITUTE   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^f MEDICAL COLLEGE OF GEORGIA   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY OF CHICAGO   (United States)

ⁱ UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^j UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^k PRINCESS MARGARET HOSPITAL   (Canada)

^l MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^m UNIVERSITY OF MARYLAND   (United States)

ⁿ UNIVERSITY OF CALIFORNIA   (United States)

^o Uniformed Serv Univ of Hlth Sci ^*  (United States)

^p UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^q CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^r WAKE FOREST SCHOOL OF MEDICINE   (United States)

^s CATHOLIC UNIVERSITY OF AMERICA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; ANDROSTENEDIOL; ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTIOXIDANT; DEXAMETHASONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENEMA; FAS ANTIGEN; FIBROBLAST GROWTH FACTOR; HALOFUGINONE; HEMOPOIETIC GROWTH FACTOR; INTERLEUKIN 11; KERATINOCYTE GROWTH FACTOR; MANGANESE SUPEROXIDE DISMUTASE; MERCAPTAMINE; MISOPROSTOL; OCTREOTIDE; PENTOXIFYLLINE; PRIMROSE OIL; PROTEIN P53; RADIOPROTECTIVE AGENT; SALAZOSULFAPYRIDINE; SHORT CHAIN FATTY ACID; SUCRALFATE; THROMBOMODULIN; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG;

CANCER RADIOTHERAPY; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; DIGESTIVE SYSTEM INJURY; FIBROSIS; GASTROINTESTINAL HEMORRHAGE; HEMATOLOGIC DISEASE; HUMAN; KIDNEY DISEASE; KIDNEY INJURY; LUNG FIBROSIS; LUNG INJURY; NONHUMAN; PRIORITY JOURNAL; PROCTITIS; RADIATION DOSE FRACTIONATION; RADIATION HAZARD; RADIATION INJURY; RADIATION PROTECTION; RADIATION RESPONSE; WHOLE BODY RADIATION; XEROSTOMIA;

ANIMALS; CENTRAL NERVOUS SYSTEM; GASTROINTESTINAL TRACT; HEMATOPOIETIC SYSTEM; HUMANS; KIDNEY; LUNG; RADIATION INJURIES; SKIN; ZEBRAFISH;

ANIMALIA;

EID: 9244246263     PISSN: 00337587     EISSN: None     Source Type: Journal    
DOI: 10.1667/RR3276     Document Type: Conference Paper

References (199)

1. C. N. Coleman, H. B. Stone, J. E. Moulder and T. C. Pellmar, Medicine. Modulation of radiation injury. Science 304, 693-694 (2004).
2. J. E. Moulder, Pharmacological intervention to prevent or ameliorate chronic radiation injuries. Semin. Radiat. Oncol. 13, 73-84 (2003).
3. C. N. Andreassen, C. Grau and J. C. Lindegaard, Chemical radioprotection: A critical review of amifostine as a cytoprotector in radiotherapy. Semin. Radiat. Oncol. 13, 62-72 (2003).
4. A. Molteni, J. E. Moulder, E. P. Cohen, W. F. Ward, B. L. Fish, J. M. Taylor, L. F. Wolfe, L. Brizio-Molteni and P. Veno, Control of radiation-induced pneumopathy and lung fibrosis by angiotensin-converting enzyme inhibitors and an angiotensin II type 1 receptor blocker. Int. J. Radiat. Biol. 76, 523-532 (2000).
5. J. E. Moulder, B. L. Fish and E. P. Cohen, ACE inhibitors and AII receptor antagonists in the treatment and prevention of bone marrow transplant nephropathy. Curr. Pharm. Des. 9, 737-749 (2003).
6. J. H. Kim, S. L. Brown, A. Kolozsvary, K. A. Jenrow, S. Ryu, M. L. Rosenblum and O. A. Carretero, Modification of radiation injury by ramipril, inhibitor of angiotensin-converting enzyme, on optic neuropathy in the rat. Radiat. Res. 161, 137-142 (2004).
7. J. L. Lefaix, S. Delanian, M. C. Vozenin, J. J. Leplat, Y. Tricaud and M. Martin, Striking regression of subcutaneous fibrosis induced by high doses of gamma rays using a combination of pentoxifylline and alpha-tocopherol: An experimental study. Int. J. Radiat. Oncol. Biol. Phys. 43, 839-847 (1999).
8. P. Okunieff, E. Augustine, J. E. Hicks, T. L. Cornelison, R. M. Altemus, B. G. Naydich, I. Ding, A. K. Huser, E. H. Abraham and L. H. Gerber, Pentoxifylline in the treatment of radiation-induced fibrosis. J. Clin. Oncol. 22, 2207-2213 (2004).
9. T. J. MacVittie and A. M. Farese, Cytokine-based treatment for acute radiation-induced myelosuppression: Preclinical and clinical perspective. In The Medical Basis for Radiation-Accident Preparedness: The Clinical Care of Victims (R. C. Ricks, M. E. Berger and F. M. O'Hara, Eds.), pp. 53-72. Parthenon Publishing Group, Boca Raton, FL, 2002.
10. F. A. Mettler, Jr. and G. L. Voelz, Major radiation exposure - what to expect and how to respond. N. Engl. J. Med. 346, 1554-1561 (2002).
11. N. Dainiak, Hematologic consequences of exposure to ionizing radiation. Exp. Hematol. 30, 513-528 (2002).
12. T. M. Seed, M. E. Dobson, D. C. Garner, T. B. Kneisler and M. H. Whitnall, Estimation of exposure using blood markers and clinical indicators. In Triage of Irradiated Personnel, pp. 7-13. Special Publication 98-2, Armed Forces Radiobiology Research Institute, Bethesda, MD, 1998.
13. N. Wald, Alterations of hematological parameters by radiation. In Triage of Irradiated Personnel, pp. B-1-B-5. AFRRI Special Publication 98-2, Armed Forces Radiobiology Research Institute, Bethesda, MD, 1998.
14. H. Kindler, D. Densow and T. M. Fliedner, Prediction of clinical course through serial determinations. In Triage of Irradiated Personnel pp. B-6-B-9. AFRRI Special Publication 98-2, Armed Forces Radiobiology Research Institute, Bethesda, MD, 1998.
15. A. M. Farese, D. B. Casey, W. G. Smith, R. M. Vigneulle, J. P. McKearn and T. J. MacVittie, Leridistim, a chimeric dual G-CSF and IL-3 receptor agonist, enhances multilineage hematopoietic recovery in a nonhuman primate model of radiation-induced myelosuppression: Effect of schedule, dose, and route of administration. Stem Cells 19, 522-533 (2001).
16. M. L. Patchen, T. J. MacVittie, B. D. Solberg, M. M. D'Alesandro and I. Brook, Radioprotection by polysaccharides alone and in combination with aminothiols. Adv. Space Res. 12, 233-248 (1992).
17. T. M. Seed and L. V. Kaspar, Acquired radioresistance of hematopoietic progenitors (granulocyte/monocyte colony-forming units) during chronic radiation leukemogenesis. Cancer Res. 52, 1469-1476 (1992).
18. T. M. Seed, Hematopoietic tissue repair under chronic low daily dose irradiation. Adv. Space Res. 18, 65-70 (1996).
19. D. W. VanBekkum, J. W. M. Visser, J. G. J. Bauman, A. H. Mulder, J. F. Eliason and A. M. DeLeeuw, Direct morphological and functional examination of murine pluripotent hemopoietic stem cells. In Hematopoietic Cellular Proliferation: An International Conference in Honor of Eugene P. Cronkite (V. P. Bond, P. Chandra and K. R. Rai, Eds.), pp. 143-149. The New York Academy of Sciences, New York, NY, 1985.
20. P. Mauch, L. Constine, J. Greenberger, W. Knospe, J. Sullivan, J. L. Liesveld and H. J. Deeg, Hematopoietic stem cell compartment: Acute and late effects of radiation therapy and chemotherapy. Int. J. Radiat. Oncol. Biol. Phys. 31, 1319-1339 (1995).
21. U. Steidl, R. Kronenwett, S. Martin and R. Haas, Molecular biology of hematopoietic stem cells. Vitam. Horm. 66, 1-28 (2003).
22. M. R. Bishop, Potential use of hematopoietic stem cells after radiation injury. Stem Cells 15 (Suppl. 2), 305-310 (1997).
23. D. L. Confer, Donor selection and management of hematopoietic cell transplantation. In The Medical Basis for Radiation-Accident Preparedness: The Clinical Care of Victims (R. C. Ricks, M. E. Berger and F. M. O'Hara, Eds.), pp. 109-116. Parthenon Publishing Group, Boca Raton, FL, 2002.
24. D. J. Grdina, J. S. Murley and Y. Kataoka, Radioprotectants: Current status and new directions. Oncology 63 (Suppl. 2), 2-10 (2002).
25. M. M. Kligerman, D. J. Glover, A. T. Turrisi, A. L. Norfleet, J. M. Yuhas, L. R. Coia, C. Simone, J. H. Glick and R. L. Goodman, Toxicity of WR-2721 administered in single and multiple doses. Int. J. Radiat. Oncol. Biol. Phys. 10, 1773-1776 (1984).
26. M. Orditura, F. De Vita, A. Belli, F. Ciaramella, M. Musico, A. Ferrigno, R. Formato, G. Abbate, M. R. Diadema and G. Catalano, Efficacy and safety profile of amifostine in the preoperative combined therapy of esophageal cancer patients. Oncol. Rep. 7, 397-400 (2000).
27. R. Boccia, Improved tolerability of amifostine with rapid infusion and optimal patient preparation. Semin. Oncol. 29, 9-13 (2002).
28. A. Van der Meeren, M. A. Mouthon, M. H. Gaugler, M. Vandamme and P. Gourmelon, Administration of recombinant human IL11 after supralethal radiation exposure promotes survival in mice: Interactive effect with thrombopoietin. Radiat. Res. 157, 642-649 (2002).
29. F. Hérodin, P. Bourin, J. F. Mayol, J. J. Lataillade and M. Drouet, Short-term injection of antiapoptotic cytokine combinations soon after lethal gamma-irradiation promotes survival. Blood 101, 2609-2616 (2003).
30. J. K. Waselenko, T. J. MacVittie, W. F. Blakely, N. Pesik, A. L. Wiley, W. E. Dickerson, H. Tsu, D. L. Confer, C. N. Coleman and N. Dainiak, Medical management of the acute radiation syndrome: Recommendations of the Strategic National Stockpile Radiation Working Group. Ann. Intern. Med. 140, 1037-1051 (2004).
31. M. Drouet, F. Mourcin, N. Grenier, J. F. Mayol, V. Leroux, F. Herodin and J. J. Sotto, The effects of ionizing radiation on stem cells and hematopoietic progenitors: The place of apoptosis and the therapeutic potential of anti-apoptosis treatments. Can. J. Physiol. Pharmacol. 80, 700-709 (2002).
32. R. van Os, C. Lamont, A. Witsell and P. M. Mauch, Radioprotection of bone marrow stem cell subsets by interleukin-1 and kit-ligand: Implications for CFU-S as the responsible target cell population. Exp. Hematol. 25, 205-210 (1997).
33. M. H. Whitnall, C. L. Wilhelmsen, L. McKinney, V. Miner, T. M. Seed and W. E. Jackson, 3rd, Radioprotective efficacy and acute toxicity of 5-androstenediol after subcutaneous or oral administration in mice. Immunopharmacol. Immunotoxicol. 24, 595-626 (2002).
34. P. Okunieff, M. Li, W. Liu, J. Sun, B. Fenton, L. Zhang and I. Ding, Keratinocyte growth factors radioprotect bowel and bone marrow but not KHT sarcoma. Am. J. Clin. Oncol. 24, 491-495 (2001).
35. K. E. Rodgers, S. Xiong and G. S. diZerega, Accelerated recovery from irradiation injury by angiotensin peptides. Cancer Chemother. Pharmacol. 49, 403-411 (2002).
36. E. Yeoh, M. Horowitz, A. Russo, T. Muecke, T. Robb, A. Maddox and B. Chatterton, Effect of pelvic irradiation on gastrointestinal function: a prospective longitudinal study. Am. J. Med. 95, 397-406 (1993).
37. P. Fransson and A. Widmark, Late side effects unchanged 4-8 years after radiotherapy for prostate carcinoma: a comparison with age-matched controls. Cancer 85, 678-688 (1999).
38. A. Fasano, Pathophysiology and management of radiation injury to the gastrointestinal tract. In The Medical Basis for Radiation-Accident Preparedness: The Clinical Care of Victims (R. C. Ricks, M. E. Berger and F. M. O'Hara, Eds.), pp. 149-160. Parthenon Publishing Group, Boca Raton, FL, 2002.
39. C. S. Potten, Radiation injury of the gastrointestinal epithelium: Current research on treatment, management, and prevention. In The Medical Basis for Radiation-Accident Preparedness: The Clinical Care of Victims (R. C. Ricks, M. E. Berger and F. M. O'Hara, Eds.), pp. 139-148. Parthenon Publishing Group, Boca Raton, FL, 2002.
40. B. A. Erickson, M. F. Otterson, J. E. Moulder and S. K. Sarna, Altered motility causes the early gastrointestinal toxicity of irradiation. Int. J. Radiat. Oncol. Biol. Phys. 28, 905-912 (1994).
41. M. F. Otterson, S. K. Sarna and J. E. Moulder, The effects of radiation on gastrointestinal motility and potential therapies. In Advances in the Treatment of Radiation Injuries: Proceedings of the 2nd Consensus Development Conference on the Treatment of Radiation Injuries (T. J. MacVittie, J. F. Weiss and D. Browne, Eds.), pp. 207-216. Elsevier, New York, 1996.
42. M. Hauer-Jensen and L. Poulakos, Experimental radiation injuries of the gastrointestinal tract. In Essentials of Experimental Surgery: Gastroenterology (S. L. Jensen, H. Gregersen, M. H. Shokouh-Amiri and F. G. Moody, Eds.). Harwood Academic Publishers, Amsterdam, 1996.
43. M. Hauer-Jensen, J. Wang and J. W. Denham, Mechanisms and modification of the radiation response of gastrointestinal organs. In Modification of Radiation Response: Cytokines, Growth Factors, and Other Biological Target (L. Milas, K. K. Ang and C. Nieder, Eds.), pp. 49-72. Springer Verlag, Heidelberg, 2002.
44. E. B. Rubenstein, D. E. Peterson, M. Schubert, D. Keefe, D. McGuire, J. Epstein, L. S. Elting, P. C. Fox, C. Cooksley and S. T. Sonis, Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 100, 2026-2046 (2004).
45. M. Hauer-Jensen, J. Wang and J. W. Denham, Bowel injury: Current and evolving management strategies. Semin. Radiat. Oncol. 13, 357-371 (2003).
46. F. Paris, Z. Fuks, A. Kang, P. Capodieci, G. Juan, D. Ehleiter, A. Haimovitz-Friedman, C. Cordon-Cardo and R. Kolesnick, Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science 293, 293-297 (2001).
47. J. G. Maj, F. Paris, A. Haimovitz-Friedman, E. Venkatraman, R. Kolesnick and Z. Fuks, Microvascular function regulates intestinal crypt response to radiation. Cancer Res. 63, 4338-4341 (2003).
48. J. W. Denham and M. Hauer-Jensen, The radiotherapeutic injury - a complex 'wound'. Radiother. Oncol. 63, 129-145 (2002).
49. J. Wang, H. Zheng, X. Ou, L. M. Fink and M. Hauer-Jensen, Deficiency of microvascular thrombomodulin and up-regulation of protease-activated receptor-1 in irradiated rat intestine: Possible link between endothelial dysfunction and chronic radiation fibrosis. Am. J. Pathol. 160, 2063-2072 (2002).
50. M. Hauer-Jensen, L. M. Fink and J. Wang, Radiation injury and the protein C pathway. Crit. Care Med. 32, S325-S330 (2004).
51. W. Dörr, K. Spekl and C. L. Farrell, Amelioration of acute oral mucositis by keratinocyte growth factor: fractionated irradiation. Int. J. Radiat. Oncol. Biol. Phys. 54, 245-251 (2002).
52. R. Neta, S. M. Stiefel and N. Ali, In lethally irradiated mice interleukin-12 protects bone marrow but sensitizes intestinal tract to damage from ionizing radiation. Ann. NY Acad. Sci. 762, 274-281 (1995).
53. H. Athanassiou, D. Antonadou, N. Coliarakis, A. Kouveli, M. Synodinou, M. Paraskevaidis, G. Sarris, G. R. Georgakopoulos, K. Panousaki and N. Throuvalas, Protective effect of amifostine during fractionated radiotherapy in patients with pelvic carcinomas: results of a randomized trial. Int. J. Radiat. Oncol. Biol. Phys. 56, 1154-1160 (2003).
54. E. L. Travis, H. D. J. Thames, S. L. Tucker, T. L. Watkins and I. Kiss, Protection of mouse jejunal crypt cells by WR-2721 after small doses of radiation. Int. J. Radiat. Oncol. Biol. Phys. 12, 807-814 (1986).
55. F. E. Halberg, S. M. LaRue, A. A. Rayner, W. M. Burnel, B. E. Powers, A. S. Chan, M. C. Schell, E. L. Gillette and T. L. Phillips, Intraoperative radiotherapy with localized radioprotection: diminished duodenal toxicity with intraluminal WR2721. Int. J. Radiat. Oncol. Biol. Phys. 21, 1241-1246 (1991).
56. J. P. Delaney, M. E. Bonsack and I. Felemovicius, Radioprotection of the rat small intestine with topical WR-2721. Cancer 74, 2379-2384 (1994).
57. M. E. Bonsack, I. Felemovicius, M. L. Baptista and J. P. Delaney, Radioprotection of the intestinal mucosa of rats by probucol. Radiat. Res. 151, 69-73 (1999).
58. M. P. Carroll, R. T. Zera, J. C. Roberts, S. E. Schlafmann, D. A. Feeney, G. R. Johnston, M. A. West and M. P. Bubrick, Efficacy of radioprotective agents in preventing small and large bowel radiation injury. Dis. Colon Rectum 38, 716-722 (1995).
59. I. Felemovicius, M. E. Bonsack, M. L. Baptista and J. P. Delaney, Intestinal radioprotection by vitamin E (alpha-tocopherol). Ann. Surg. 222, 504-510 (1995).
60. A. H. McArdle, C. Wittnich, C. R. Freeman and W. P. Duguid, Elemental diet as prophylaxis against radiation injury. Histological and ultrastructural studies. Arch. Surg. 120, 1026-1032 (1985).
61. H. L. Guo, D. Wolfe, M. W. Epperly, S. Huang, K. Liu, J. C. Glorioso, J. Greenberger and D. Blumberg, Gene transfer of human manganese superoxide dismutase protects small intestinal villi from radiation injury. J. Castrointest. Surg. 7, 229-236 (2003).
62. A. V. Gudkov and E. A. Komarova, The role of p53 in determining sensitivity to radiotherapy. Nat. Rev. Cancer 3, 117-129 (2003).
63. E. A. Komarova, R. V. Kondratov, K. Wang, K. Christov, T. V. Golovkina, J. R. Goldblum and A. V. Gudkov, Dual effect of p53 on radiation sensitivity in vivo: p53 promotes hematopoietic injury, but protects from gastro-intestinal syndrome in mice. Oncogene 23, 3265-3271 (2004).
64. Y. Tezuka, S. Yonezawa, I. Maruyama, Y. Matsushita, T. Shimizu, H. Obama, M. Sagara, K. Shirao, C. Kusano and E. Sato, Expression of thrombomodulin in esophageal squamous cell carcinoma and its relationship to lymph node metastasis. Cancer Res. 55, 4196-4200 (1995).
65. T. Suehiro, M. Shimada, T. Matsumata, A. Taketomi, K. Yamamoto and K. Sugimachi, Thrombomodulin inhibits intrahepatic spread in human hepatocellular carcinoma. Hepatology 21, 1285-1290 (1995).
66. S. J. Kim, E. Shiba, H. Ishii, T. Inoue, T. Taguchi, Y. Tanji, Y. Kimoto, M. Izukura and S. Takai, Thrombomodulin is a new biological and prognostic marker for breast cancer: An immunohistochemical study. Anticancer Res. 17, 2319-2323 (1997).
67. M. Hamatake, T. Ishida, T. Mitsudomi, K. Akazawa and K. Sugimachi, Prognostic value and clinicopathological correlation of thrombomodulin in squamous cell carcinoma of the human lung. Clin. Cancer Res. 2, 763-766 (1996).
68. 5 integrin. J. Biol. Chem. 276, 10952-10962 (2001).
69. M. Tabata, K. Sugihara, S. Yonezawa, S. Yamashita and I. Maruyama, An immunohistochemical study of thrombomodulin in oral squamous cell carcinoma and its association with invasive and metastatic potential. J. Oral Pathol. Med. 26, 258-264 (1997).
70. Y. J. Yin, Z. Salah, M. Maoz, S. C. Ram, S. Ochayon, G. Neufeld, S. Katzav and R. Bar-Shavit, Oncogenic transformation induces tumor angiogenesis: A role for PARI activation. FASEB J. 17, 163-174 (2003).
71. Y. Zhang, H. Weiler-Guettler, J. Chen, O. Wilhelm, Y. Deng, F. Qiu, K. Nakagawa, M. Klevesath, S. Wilhelm and P. P. Nawroth, Thrombomodulin modulates growth of tumor cells independent of its anticoagulant activity. J. Clin. Invest. 101, 1301-1309 (1998).
72. M. L. Nierodzik, K. Chen, K. Takeshita, J. J. Li, Y. Q. Huang, X. S. Feng, M. R. D'Andrea, P. Andrade-Gordon and S. Karpatkin, Protease-activated receptor 1 (PAR-1) is required and rate-limiting for thrombin-enhanced experimental pulmonary metastasis. Blood 92, 3694-3700 (1998).
73. R. A. Patchell, The management of brain metastases. Cancer Treat. Rev. 29, 533-540 (2003).
74. J. R. Crossen, D. Garwood, E. Glatstein and E. A. Neuwelt, Neurobehavioral sequelae of cranial irradiation in adults: A review of radiation-induced encephalopathy. J. Clin. Oncol. 12, 627-642 (1994).
75. D. D. Roman and P. W. Sperduto, Neuropsychological effects of cranial radiation: Current knowledge and future directions. Int. J. Radiat. Oncol. Biol. Phys. 31, 983-998 (1995).
76. O. K. Abayomi, Pathogenesis of irradiation-induced cognitive dysfunction. Acta Oncol. 35, 659-663 (1996).
77. T. C. Pellmar and D. L. Lepinski, Gamma radiation (5-10 Gy) impairs neuronal function in the guinea pig hippocampus. Radiat. Res. 136, 255-261 (1993).
78. H. G. Kuhn, H. Dickinson-Anson and F. H. Gage, Neurogenesis in the dentate gyrus of the adult rat: Age-related decrease of neuronal progenitor proliferation. J. Neurosci. 16, 2027-2033 (1996).
79. P. S. Eriksson, E. Perfilieva, T. Bjork-Eriksson, A. M. Alborn, C. Nordborg, D. A. Peterson and F. H. Gage, Neurogenesis in the adult human hippocampus. Nat. Med. 4, 1313-1317 (1998).
80. E. Tada, J. M. Parent, D. H. Lowenstein and J. R. Fike, X-irradiation causes a prolonged reduction in cell proliferation in the dentate gyrus of adult rats. Neuroscience 99, 33-41 (2000).
81. S. Mizumatsu, M. L. Monje, D. R. Morhardt, R. Rola, T. D. Palmer and J. R. Fike, Extreme sensitivity of adult neurogenesis to low doses of X-irradiation. Cancer Res. 63, 4021-4027 (2003).
82. M. L. Monje, S. Mizumatsu, J. R. Fike and T. D. Palmer, Irradiation induces neural precursor-cell dysfunction. Nat. Med. 8, 955-962 (2002).
83. T. M. Madsen, P. E. Kristjansen, T. G. Bolwig and G. Wortwein, Arrested neuronal proliferation and impaired hippocampal function following fractionated brain irradiation in the adult rat. Neuroscience 119, 635-642 (2003).
84. R. Rola, J. Raber, A. Rizk, S. Otsuka, S. R. VandenBerg, D. R. Morhardt and J. R. Fike, Radiation-induced impairment of hippocampal neurogenesis is associated with cognitive deficits in young mice. Radiat. Res. 162, 39-47 (2004).
85. J. M. Tolliver and T. C. Pellmar, Ionizing radiation alters neuronal excitability in hippocampal slices of the guinea pig. Radiat. Res. 112, 555-563 (1987).
86. T. C. Pellmar, D. A. Schauer and G. H. Zeman, Time- and dose-dependent changes in neuronal activity produced by X radiation in brain slices. Radiat. Res. 122, 209-214 (1990).
87. G. E. Sheline, W. M. Wara and V. Smith, Therapeutic irradiation and brain injury. Int. J. Radiat. Oncol. Biol. Phys. 6, 1215-1228 (1980).
88. J. W. Hopewell, Radiation injury to the central nervous system. Med. Pediatr. Oncol. (Suppl. 1), 1-9 (1998).
89. P. J. Tofilon and J. R. Fike, The radioresponse of the central nervous system: A dynamic process. Radiat. Res. 153, 357-370 (2000).
90. K. K. Ang, Radiobiology of the central nervous system. In Neuro-Oncology: The Essentials (M. Bernstein and M. S. Berger, Eds.), pp. 160-168. Thieme, New York, 2000.
91. T. E. Schultheiss, L. E. Kun, K. K. Ang and L. C. Stephens, Radiation response of the central nervous system. Int. J. Radiat. Oncol. Biol. Phys. 31, 1093-1112 (1995).
92. A. N. Martins, R. E. Severance, J. M. Henry and T. F. Doyle, Experimental delayed radiation necrosis of the brain. Part 1: Effect of early dexamethasone treatment. J. Neurosurg. 51, 587-596 (1979).
93. E. Tada, K. Matsumoto, K. Kinoshita, T. Furuta and T. Ohmoto, The protective effect of dexamethasone against radiation damage induced by interstitial irradiation in normal monkey brain. Neurosurgery 41, 209-217 (1997).
94. C. Nieder, N. Andratschke, R. E. Price, B. Rivera and K. K. Ang, Innovative prevention strategies for radiation necrosis of the central nervous system. Anticancer Res. 22, 1017-1023 (2002).
95. C. Nieder, R. E. Price, B. Rivera, N. Andratschke and K. K. Ang, Experimental data for administration of insulin-like growth factor 1 (IGF-1) and basic fibroblast growth factor (bFGF) for prevention of radiation myelopathy. Strahlenther. Onkol. 178, 147-152 (2002).
96. J. L. Daigle, J. H. Hong, C. S. Chiang and W. H. McBride, The role of tumor necrosis factor signaling pathways in the response of murine brain to irradiation. Cancer Res. 61, 8859-8865 (2001).
97. J. H. Hong, C. S. Chiang, I. L. Campbell, J. R. Sun, H. R. Withers and W. H. McBride, Induction of acute phase gene expression by brain irradiation. Int. J. Radiat. Oncol. Biol. Phys. 33, 619-626 (1995).
98. L. Vallieres, I. L. Campbell, F. H. Gage and P. E. Sawchenko, Reduced hippocampal neurogenesis in adult transgenic mice with chronic astrocytic production of interleukin-6. J. Neurosci. 22, 486-492 (2002).
99. C. L. Limoli, E. Giedzinski, R. Rola, S. Otsuka, T. D. Palmer and J. R. Fike, Radiation response of neural precursor cells: Linking cellular sensitivity to cell cycle checkpoints, apoptosis and oxidative stress. Radiat. Res. 161, 17-27 (2004).
100. E. L. Travis, Relative radiosensitivity of the human lung. Adv. Radiat. Biol. 12, 205-238 (1987).
101. L. B. Marks, X. Yu, Z. Vujaskovic, W. Small, Jr., R. Folz and M. S. Anscher, Radiation-induced lung injury. Semin. Radiat. Oncol. 13, 333-345 (2003).
102. E. L. Travis, Organizational response of normal tissues to irradiation. Semin. Radiat. Oncol. 11, 184-196 (2001).
103. B. Emami, J. Lyman, A. Brown, L. Coia, M. Goitein, J. E. Munzenrider, B. Shank, L. J. Solin and M. Wesson, Tolerance of normal tissue to therapeutic irradiation. Int. J. Radiat. Oncol. Biol. Phys. 21, 109-122 (1991).
104. Z. Vujaskovic, L. B. Marks and M. S. Anscher, The physical parameters and molecular events associated with radiation-induced lung toxicity. Semin. Radiat. Oncol. 10, 296-307 (2000).
105. C. K. Haston, X. Zhou, L. Gumbiner-Russo, R. Irani, R. Dejournett, X. Gu, M. Weil, C. I. Amos and E. L. Travis, Universal and radiation-specific loci influence murine susceptibility to radiation-induced pulmonary fibrosis. Cancer Res. 62, 3782-3788 (2002).
106. E. L. Travis and S. L. Tucker, The relationship between functional assays of radiation response in the lung and target cell depletion. Br. J. Cancer. 7 (Suppl.), 304-319 (1986).
107. T. L. Phillips and L. Margolis, Radiation pathology and the clinical response of lung and esophagus. Front. Radiation Ther. Oncol. 6, 254-273 (1972).
108. C. Nieder, B. Jeremic, S. Astner and M. Molls, Radiotherapy-induced lung toxicity: Risk factors and prevention strategies. Anticancer Res. 23, 4991-4998 (2003).
109. J. P. Geraci, M. S. Mariano, K. L. Jackson, D. A. Taylor and E. R. Still, Effects of dexamethasone on late radiation injury following partial-body and local organ exposures. Radiat. Res. 129, 61-70 (1992).
110. Z. Vujaskovic, Q. F. Feng, Z. N. Rabbani, T. V. Samulski, M. S. Anscher and D. M. Brizel, Assessment of the protective effect of amifostine on radiation-induced pulmonary toxicity. Exp. Lung Res. 28, 577-590 (2002).
111. W. F. Ward, A. Molteni, C. H. Ts'ao, Y. T. Kim and J. M. Hinz, Radiation pneumotoxicity in rats: Modification by inhibitors of angiotensin converting enzyme. Int. J. Radiat. Oncol. Biol. Phys. 22, 623-625 (1992).
112. L. W. Wang, X. L. Fu, R. Clough, G. Sibley, M. Fan, G. C. Bentel, L. B. Marks and M. S. Anscher, Can angiotensin-converting enzyme inhibitors protect against symptomatic radiation pneumonitis? Radiat. Res. 153, 405-410 (2000).
113. R. K. Coker, G. J. Laurent, P. K. Jeffery, R. M. du Bois, C. M. Black and R. J. McAnulty, Localisation of transforming growth factor 1 and 3 mRNA transcripts in normal and fibrotic human lung. Thorax 56, 549-556 (2001).
114. N. H. Terry, J. Brinkley, A. J. Doig, J. Ma, N. Patel, R. A. White, N. Mahajan and Y. Kang, Cellular kinetics of murine lung: Model system to determine basis for radioprotection with keratinocyte growth factor. Int. J. Radiat. Oncol. Biol. Phys. 58, 435-444 (2004).
115. E. S. Yi, S. T. Williams, H. Lee, D. M. Malicki, E. M. Chin, S. Yin, J. Tarpley and T. R. Ulich, Keratinocyte growth factor ameliorates radiation- and bleomycin-induced lung injury and mortality. Am. J. Pathol. 149, 1963-1970 (1996).
116. Z. Vujaskovic, I. Batinic-Haberle, Z. N. Rabbani, Q. F. Feng, S. K. Kang, I. Spasojevic, T. V. Samulski, I. Fridovich, M. W. Dewhirst and M. S. Anscher, A small molecular weight catalytic metalloporphyrin antioxidant with superoxide dismutase (SOD) mimetic properties protects lungs from radiation-induced injury. Free Radic. Biol. Med. 33, 857-863 (2002).
117. M. W. Epperly, V. E. Kagan, C. A. Sikora, J. E. Gretton, S. J. Defilippi, D. Bar-Sagi and J. S. Greenberger, Manganese superoxide dismutase-plasmid/ liposome (MnSOD-PL) administration protects mice from esophasitis associated with fractionated radiation. Int. J. Cancer 96, 221-231 (2001).
118. J. R. Cassady, Clinical radiation nephropathy. Int. J. Radiat. Oncol. Biol. Phys. 31, 1249-1256 (1995).
119. E. P. Cohen, Radiation nephropathy after bone marrow transplantation. Kidney Int. 58, 903-918 (2000).
120. E. P. Cohen, J. E. Moulder, B. L. Fish and P. Hill, Prophylaxis of experimental bone marrow transplant nephropathy. J. Lab. Clin. Med. 124, 371-380 (1994).
121. R. Miralbell, S. Bieri, B. Mermillod, C. Helg, G. Sancho, B. Pastoors, A. Keller, J. M. Kurtz and B. Chapuis, Renal toxicity after allogeneic bone marrow transplantation: The combined effects of total-body irradiation and graft-versus-host disease. J. Clin. Oncol. 14, 579-585 (1996).
122. N. J. Tarbell, E. C. Guinan, L. Chin, P. Manch and H. J. Weinstein, Renal insufficiency after total body irradiation for pediatric bone marrow transplantation. Radiother. Oncol. 18 (Suppl.), 139-142 (1990).
123. B. Lambert, M. Cybulla, S. M. Weiner, C. Van de Viele, H. Ham, R. A. Dierckx and A. Otte, Renal toxicity after radionuclide therapy. Radiat. Res. 161, 607-611 (2004).
124. E. P. Cohen, J. E. Moulder and M. E. Robbins, Radiation nephropathy caused by yttrium 90. Lancet 358, 1102-1103 (2001).
125. S. Giralt, W. Bensinger, M. Goodman, D. Podoloff, J. Eary, R. Wendt, R. Alexanian, D. Weber, D. Maloney and R. Champlin, 166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: Results of two phase 1/2 trials. Blood 102, 2684-2691 (2003).
126. E. P. Cohen and M. E. Robbins, Radiation nephropathy. Semin. Nephrol. 23, 486-499 (2003).
127. E. P. Cohen, B. L. Fish and J. E. Moulder, The renin-angiotensin system in experimental radiation nephropathy. J. Lab. Clin. Med. 139, 251-257 (2002).
128. Z. X. Liao and E. L. Travis, Unilateral nephrectomy 24 hours after bilateral kidney irradiation reduces damage to the function and structure of the remaining kidney. Radiat. Res. 139, 290-299 (1994).
129. A. Kuin, J. J. Kruse and F. A. Stewart, Proteinuria and vascular changes after renal irradiation: The role of reactive oxygen species (ROS) and vascular endothelial growth factor (Vegf). Radiat Res. 159, 174-181 (2003).
130. G. Stevens, M. Joiner, B. Joiner, H. Johns and J. Denekamp, Early detection of damage following bilateral renal irradiation in the mouse. Radiother. Oncol. 20, 124-131 (1991).
131. J. P. Geraci, M. C. Sun and M. S. Mariano, Amelioration of radiation nephropathy in rats by postirradiation treatment with dexamethasone and/or captopril. Radiat. Res. 143, 58-68 (1995).
132. M. E. Robbins, S. M. Bonsib, J. A. Soranson, G. D. Wilson, A. Ikeda, M. Rezvani, S. J. Golding, E. Whitehouse and J. W. Hopewell, Radiation-induced changes in glomerular and tubular cell kinetics and morphology following irradiation of a single kidney in the pig. Int. J. Radiat. Oncol. Biol. Phys. 32, 1071-1081 (1995).
133. P. J. Hoopes, E. L. Gillette and S. A. Benjamin. The pathogenesis of radiation nephropathy in the dog. Radiat. Res. 104, 406-419 (1985).
134. D. M. Prescott, P. J. Hoopes and D. E. Thrall, Modification of radiation damage in the canine kidney by hyperthermia: A histologic and functional study. Radiat. Res. 124, 317-325 (1990).
135. E. M. van Kleef, C. Zurcher, Y. G. Oussoren, J. A. te Poele, M. A. van der Valk, M. M. Niemer-Tucker, M. H. van der Hage, J. J. Broerse, M. E. Robbins and F. A. Stewart, Long-term effects of total-body irradiation on the kidney of Rhesus monkeys. Int. J. Radiat. Biol. 76, 641-648 (2000).
136. M. Sharma, R. Sharma, X. L. Ge, B. L. Fish, E. T. McCarthy, V. J. Savin, E. P. Cohen and J. E. Moulder, Early detection of radiation-induced glomerular injury by albumin permeability assay. Radiat. Res. 155, 474-480 (2001).
137. M. E. Robbins and S. M. Bonsib, Radiation nephropathy: A review. Scanning Microsc. 9, 535-560 (1995).
138. E. P. Cohen, B. L. Fish and J. E. Moulder, Successful brief captopril treatment in experimental radiation nephropathy. J. Lab. Clin. Med. 129, 536-547 (1997).
139. E. P. Cohen, A. Molteni, P. Hill, B. L. Fish, W. F. Ward, J. E. Moulder and F. A. Carone, Captopril preserves function and ultrastructure in experimental radiation nephropathy. Lab. Invest. 75, 349-360 (1996).
140. J. J. Kruse, J. A. te Poele, A. Velds, R. M. Kerkhoven, L. J. Boersma, N. S. Russell and F. A. Stewart, Identification of differentially expressed genes in mouse kidney after irradiation using microarray analysis. Radiat. Res. 161, 28-38 (2004).
141. M. E. Robbins, W. Zhao, C. S. Davis, S. Toyokuni and S. M. Bonsib, Radiation-induced kidney injury: A role for chronic oxidative stress? Micron 33, 133-141 (2002).
142. W. Zhao, Y. O'Malley, S. Wei and M. E. Robbins, Irradiation of rat tubule epithelial cells alters the expression of gene products associated with the synthesis and degradation of extracellular matrix. Int. J. Radiat. Biol. 76, 391-402 (2000).
143. W. Zhao, Y. O'Malley and M. E. Robbins, Irradiation of rat mesangial cells alters the expression of gene products associated with the development of renal fibrosis. Radiat. Res. 152, 160-169 (1999).
144. E. P. Cohen, S. A. Bonsib, E. Whitehouse, J. W. Hopewell and M. E. Robbins, Mediators and mechanisms of radiation nephropathy. Proc. Soc. Exp. Biol. Med. 223, 218-225 (2000).
145. E. P. Cohen, S. Hussain and J. E. Moulder, Successful treatment of radiation nephropathy with angiotensin II blockade. Int. J. Radiat. Oncol. Biol. Phys. 55, 190-193 (2003).
146. E. P. Cohen and C. A. Lawton, Pathogenesis, prevention and management of radiation nephropathy. In Current Radiation Oncology (J. S. Tobias and P. R. M. Thomas, Eds.), pp. 94-109. Oxford University Press, New York, 1998.
147. A. W. Asscher, Prevention of renal damage by X rays. Br. J. Radiol. 38, 533-535 (1965).
148. M. V. Williams and J. Denekamp, Modification of the radiation response of the mouse kidney by misonidazole and WR-2721. Int. J. Radiat. Oncol. Biol. Phys. 9, 1731-1736 (1983).
149. S. S. Donaldson, P. S. Moskowitz, J. W. Evans and L. F. Fajardo, Protection from radiation nephropathy by WR-2721. Radiat. Res. 97, 414-423 (1984).
150. M. Steinert, M. Weiss, P. Gottlober, D. Belyi, O. Gergel, V. Bebeshko, N. Nadejina, I. Galstian, G. Wagemaker and R. U. Peter, Delayed effects of accidental cutaneous radiation exposure: Fifteen years of follow-up after the Chernobyl accident. J. Am. Acad. Dermatol. 49, 417-423 (2003).
151. T. Hirama, S. Tanosaki, S. Kandatsu, N. Kuroiwa, T. Kamada, H. Tsuji, S. Yamada, H. Katoh, N. Yamamoto and M. Akashi, Initial medical management of patients severely irradiated in the Tokaimura criticality accident. Br. J. Radiol. 76, 246-253 (2003).
152. J. W. Hopewell, The skin: Its structure and response to ionizing radiation. Int. J. Radiat. Biol. 57, 751-773 (1990).
153. S. B. Field, R. L. Morgan and R. Morrison, The response of human skin to irradiation with x-rays or fast neutrons. Int. J. Radiat. Oncol. Biol. Phys. 1, 481-486 (1976).
154. V. Vegesna, H. R. Withers, F. E. Holly and W. H. McBride, The effect of local and systemic irradiation on impairment of wound healing in mice. Radiat. Res. 135, 431-433 (1993).
155. J. O. Archambeau, A. Ines and L. F. Fajardo, Response of swine skin microvasculature to acute single exposures of X rays: Quantification of endothelial changes. Radiat. Res. 98, 37-51 (1984).
156. I. Turesson, The progression rate of late radiation effects in normal tissue and its impact on dose-response relationships. Radiother. Oncol. 15, 217-226 (1989).
157. A. Burger, H. Loffler, M. Bamberg and H. P. Rodemann, Molecular and cellular basis of radiation fibrosis. Int. J. Radiat. Biol. 73, 401-408 (1998).
158. R. Gorodetsky, W. H. McBride, H. R. Withers and G. G. Miller, Effect of fibroblast implants on wound healing of irradiated skin - Assay of wound strength and quantitative immunohistology of collagen. Radiat. Res. 125, 181-186 (1991).
159. V. Vegesna, W. H. McBride, J. M. Taylor and H. R. Withers, The effect of interleukin-1 beta or transforming growth factor-beta on radiation-impaired murine skin wound healing. J. Surg. Res. 59, 699-704 (1995).
160. M. Martin, J. L. Lefaix, P. Pinton, F. Crechet and F. Daburon, Temporal modulation of TGF-1 and -actin gene expression in pig skin and muscular fibrosis after ionizing radiation. Radiat. Res. 134, 63-70 (1993).
161. K. C. Flanders, C. D. Sullivan, M. Fujii, A. Sowers, M. A. Anzano, A. Arabshahi, C. Major, C. Deng, A. Russo and A. B. Roberts, Mice lacking Smad3 are protected against cutaneous injury induced by ionizing radiation. Am. J. Pathol. 160, 1057-1068 (2002).
162. S. Xavier, E. Piek, M. Fujii, D. Javelaud, A. Mauviel, K. C. Flanders, A. M. Samuni, A. Felici, M. Reiss and A. Russo, Amelioration of radiation-induced fibrosis: Inhibition of transforming growth factor-beta signalins by halofuginone. J. Biol. Chem. 279, 15167-15176 (2004).
163. V. Meineke, K. Muller, R. Ridi, N. Cordes, F. M. Kohn, A. Mayerhofer, J. Ring and D. van Beuningen, Development and evaluation of a skin organ model for the analysis of radiation effects. Strahlenther. Onkol. 180, 102-108 (2004).
164. Z. Goldberg, C. W. Schwietert, B. Lehnert, R. Stern and I. Nami, Effects of low-dose ionizing radiation on gene expression in human skin biopsies. Int. J. Radiat. Oncol. Biol. Phys. 58, 567-574 (2004).
165. S. Boisnic, M. C. Branchet-Gumila, D. Nizri and L. Ben Slama, Histochemical and biochemical modifications induced by experimental irradiation of human skin maintained in survival conditions and modulation by application of an emulsion containing trolamine. Int. J. Tissue React. 25, 9-18 (2003).
166. U. Behrends, R. U. Peter, R. Hintermeier-Knabe, G. Eissner, E. Holler, G. W. Bornkamm, S. W. Caughman and K. Degitz, Ionizing radiation induces human intercellular adhesion molecule-1 in vitro. J. Invest. Dermatol. 103, 726-730 (1994).
167. G. M. Morris, J. W. Hopewell, M. Harold, G. A. Ross, N. M. Nadejina, I. Gusev and I. Flockhart, Modulation of the cell kinetics of pig skin by the topical application of evening primrose oil or Lioxasol. Cell Prolif. 30, 311-323 (1997).
168. B. Wen, E. Deutsch, P. Opolon, A. Auperin, V. Frascogna, E. Connault and J. Bourhis, n-3 polyunsaturated fatty acids decrease mucosal/epidermal reactions and enhance antitumour effect of ionising radiation with inhibition of tumour angiogenesis. Br. J. Cancer 89, 1102-1107 (2003).
169. L. Liang, D. Hu, W. Liu, J. P. Williams, P. Okunieff and I. Ding, Celecoxib reduces skin damage after radiation: Selective reduction of chemokine and receptor mRNA expression in irradiated skin but not in irradiated mammary tumor. Am. J. Clin. Oncol. 26, S114-S121 (2003).
170. S. Delanian, F. Baillet, J. Huart, J. L. Lefaix, C. Maulard and M. Housset, Successful treatment of radiation-induced fibrosis using liposomal Cu/Zn superoxide dismutase: Clinical trial. Radiother. Oncol. 32, 12-20 (1994).
171. S. Delanian, S. Balla-Mekias and J. L. Lefaix, Striking regression of chronic radiotherapy damage in a clinical trial of combined pentoxifylline and tocopherol. J. Clin. Oncol. 17, 3283-3290 (1999).
172. M. M. Barr, Super models. Physiol. Genomics 13, 15-24 (2003).
173. R. H. Schiestl, S. Igarashi and P. J. Hastings, Analysis of the mechanism for reversion of a disrupted gene. Genetics 119, 237-247 (1988).
174. R. H. Schiestl, Nonmutagenic carcinogens induce intrachromosomal recombination in yeast. Nature 337, 285-288 (1989).
175. R. J. Brennan and R. H. Schiestl, Persistent genomic instability in the yeast Saccharomyces cerevisiae induced by ionizing radiation and DNA-damaging agents. Radiat. Res. 155, 768-777 (2001).
176. A. A. Aboobaker and M. L. Blaxter, Medical significance of Caenorhabditis elegans. Ann. Med. 32, 23-30 (2000).
177. L. Stergiou and M. O. Hengartner, Death and more: DNA damage response pathways in the nematode C. elegans. Cell Death Differ. 11, 21-28 (2004).
178. A. Gartner, S. Milstein, S. Ahmed, J. Hodgkin and M. O. Hengartner, A conserved checkpoint pathway mediates DNA damage-induced apoptosis and cell cycle arrest in C. elegans. Mol. Cell 5, 435-443 (2000).
179. X. Deng, E. R. Hofmann, A. Villanueva, O. Hobert, P. Capodieci, D. R. Veach, X. Yin, L. Campodonico, A. Glekas and R. Kolesnick, Caenorhabditis elegans ABL-1 antagonizes p53-mediated germline apoptosis after ionizing radiation. Nat. Genet. 36, 906-912 (2004).
180. R. S. Rasooly, D. Henken, N. Freeman, L. Tompkins, D. Badman, J. Briggs and A. T. Hewitt, Genetic and genomic tools for zebrafish research: The NIH zebrafish initiative. Dev. Dyn. 228, 490-496 (2003).
181. D. Traver, A. Winzeler, H. M. Stern, E. A. Mayhall, D. M. Langenau, J. A. Kutok, A. T. Look and L. I. Zon, Effects of lethal irradiation in zebrafish and rescue by hematopoietic cell transplantation. Blood 104, 1298-1305 (2004).
182. D. M. Langenau, A. A. Ferrando, D. Traver, J. L. Kutok, J. P. Hezel, J. P. Kanki, L. I. Zon, A. T. Look and N. S. Trede, In vivo tracking of T cell development, ablation, and engraftment in transgenic zebrafish. Proc. Natl. Acad. Sci. USA 101, 7369-7374 (2004).
183. C. Mothersill, D. Rea, E. G. Wright, S. A. Lorimore, D. Murphy, C. B. Seymour and K. O'Malley, Individual variation in the production of a 'bystander signal' following irradiation of primary cultures of normal human urothelium. Carcinogenesis 22, 1465-1471 (2001).
184. J. E. Moulder, M. E. Robbins, E. P. Cohen, J. W. Hopewell and W. F. Ward, Pharmacologic modification of radiation-induced late normal tissue injury. Cancer Treat. Res. 93, 129-151 (1998).
185. M. H. Barcellos-Hoff, How do tissues respond to damage at the cellular level? The role of cytokines in irradiated tissues. Radiat. Res. 150 (Suppl.), S109-S120 (1998).
186. M. J. Bissell, The differentiated state of normal and malignant cells or how to define a "normal" cell in culture. Int. Rev. Cytol. 70, 27-100 (1981).
187. D. P. Bottaro, A. Liebmann-Vinson and M. A. Heidaran, Molecular signaling in bioengineered tissue microenvironments. Ann. NY Acad. Sci. 961, 143-153 (2002).
188. P. G. Komarov, E. A. Komarova, R. V. Kondratov, K. Christov-Tselkov, J. S. Coon, M. V. Chernov and A. V. Gudkov, A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 285, 1733-1737 (1999).
189. M. E. C. Robbins and W. Zhao, Chronic oxidative stress and radiation-induced late normal tissue injury: A review. Int. J. Radiat. Biol. 80, 251-259 (2004).
190. Current Good Manufacturing Practice in manufacturing, processing, packing, or holding of drugs. Title 21 Code of Federal Regulations, part 210, 2002.
191. T. Kennedy, Managing the drug discovery/development interface. Drug Discov. Today 10, 436-444 (1997).
192. H. Olson, G. Betton, D. Robinson, K. Thomas, A. Monro, G. Kolaja, P. Lilly, J. Sanders, G. Sipes and A. Heller, Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul. Toxicol. Pharmacol. 32, 56-67 (2000).
193. C. K. Grieshaber, Agent-directed preclinical toxicology for new antineoplastic drugs. In Cytotoxic Anticancer Drugs: Models and Concepts for Drug Discovery and Development (F. A. Valeriote, T. H. Corbett and L. H. Baker, Eds.), pp. 247-260. Kluwer Academic Publishers, Boston, 1992.
194. J. E. Tomaszewski and A. C. Smith, Chapter 23. Safety Testing of Antitumor Agents. In Comprehensive Toxicology, Toxicity Testing and Evaluation (P. D. Williams and G. H. Hottendorf, Eds.), Vol. 2, pp. 299-309. Elsevier, Oxford, 1997.
195. J. T. Johnson, S. Decker, D. Zaharevitz, L. V. Rubinstein, J. M. Venditti, S. Schepartz, S. Kalyandrug, M. Christian, S. Arbuck and E. A. Sausville, Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br. J. Cancer 84, 1424-1431 (2001).
196. J. E. Tomaszewski, A. C. Smith, J. M. Covey, S. J. Donohue, J. K. Rhie and K. M. Schweikart, Chapter 17. Relevance of preclinical pharmacology and toxicology to Phase I trial extrapolation techniques. Relevance of animal toxicology. In Anticancer Drug Design (B. C. Baguley, Ed.), pp. 301-328. Academic Press, San Diego, 2001.
197. A. Pessina, B. Albella, M. Bayo, J. Bueren, P. Brantom, S. Casati, C. Croera, G. Gagliardi, P. Foti and L. Gribaldo, Application of the CFU-GM assay to predict acute drug-induced neutropenia: an international blind trial to validate a prediction model for the maximum tolerated dose (MTD) of myelosuppressive xenobiotics. Toxicol. Sci. 75, 355-367 (2003).
198. New drug and biological drug products: Evidence needed to demonstrate effectiveness of new drugs when human efficacy studies are not ethical or feasible. Fed. Regist. 67, 37988-37998 (2002).
199. Good Laboratory Practice for nonclinical laboratory studies. Title 21 Code of Federal Regulations, part 58, 2002.